Hepatorenal syndrome in cirrhosis: Pathogenesis and treatment

Gastroenterology

Volumn 122, Issue 6, 2002, Pages 1658-1676

  Arroyo, Vicente ^a   Guevara, Mónica ^a   Ginès, Pere ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE;

ALCOHOL LIVER DISEASE; ASCITES; BACTERIAL INFECTION; CREATININE BLOOD LEVEL; HEART OUTPUT; HEPATORENAL SYNDROME; HUMAN; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; PATHOGENESIS; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SPLANCHNIC BLOOD FLOW; TOXIC HEPATITIS; VIRUS HEPATITIS;

EID: 0036098337     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.33575     Document Type: Article

References (187)

1. Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis
2. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis
3. The hepatorenal syndrome
4. Hepatorenal syndrome
5. Pharmacological treatment of the hepatorenal syndrome in cirrhotic patients
6. Ascites and hepatorenal syndrome during cirrhosis: Two entities or the continuation of the same complication?
7. Hepatorenal syndrome
8. Hepatorenal syndrome and ascites-questions and answers
9. Renal failure in liver disease
10. New challenge of hepatorenal syndrome. Prevention and treatment
11. A liver kidney syndrome. Clinical, pathological and experimental studies
12. Occurrence, distribution and pathogenesis of socalled liver death and/or hepatorenal syndrome
13. Liver trauma and the hepatorenal syndrome
14. Electrolyte and circulatory changes in terminal liver failure
15. Renal failure in Laennec's cirrhosis. II. Sinmultaneous determination of cardiac output and renal hemodynamics
16. The kidney in cirrhosis. II. Disorders in renal function
17. Renal circulation in cirrhosis: Observations based on catheterization of renal vain
18. Renal failure in patients with cirrhosis of the liver. II. Factors influencing maximal urinary flow rate
19. Renal failure in patients with cirrhosis of the liver. Evaluation of intrarenal blood flow by para-aminohippurate extration and response to angiotensin
20. Renal failure in the patient with cirrhosis. The role of active vasoconstriction
21. The plasma volume in Laennec's cirrhosis of the liver
22. Plasma volume in cirrhosis of the liver. Its relation to portal hypertension, ascites and renal failure
23. Renal failure in Laennec's cirrhosis of the liver. I. Description of clinical and laboratory features
24. The cardiac output in Laennec's cirrhosis
25. Treatment of ascites by reinfusion of concentrated peritoneal fluid: Review of 318 procedures in 210 patients
26. Peritoneo-venous shunting for ascites
27. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease
28. Recovery from hepatorenal syndrome after orthotopic liver transplantation
29. Plasma renin levels in hepatic cirrhosis. Relationship to functional renal failure
30. Sympathetic nervous activity, reninangiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion
31. Sympathetic nervous activity and renal and systemic hemodynamics in cirrhosis: Plasma norepinephrine concentration, hepatic extraction, and renal release
32. Prostaglandins: Modulators of renal function and pressor resistance in chronic liver disease
33. Urinary excretion of 6-keto-prostaglandin F1-alpha, thromboxane B2 and prostaglandin E2 in cirrhosis with ascites. Relationship to functional renal failure (hepatorenal syndrome)
34. Immunohistochemical distribution of renal prostaglandin endoperoxide synthase and prostacyclin synthase: Diminished endoperoxide synthase in the hepatorenal syndrome
35. Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis
36. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis
37. Role of vasopressin in abnormal water excretion in cirrhotic patients
38. Renal kallikrein excretion in cirrhotics with ascites: Relationship to renal hemodynamics
39. Renal function abnormalities prostaglandins and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis
40. Effect of blockade of angiotensin II on blood pressure, renin and aldosterone in cirrhosis
41. Effect of angiotensin II blockade on systemic and hepatic hemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites
42. Effect of V1-vasopressin and angiotensin-II blockade on arterial pressure and endogenous vasoconstrictor systems in conscious rats with cirrhosis and ascites
43. Sympathetic tone modulates portal venous pressure in alcoholic cirrhosis
44. Impared cardiovascular responsiveness in liver disease
45. Angiotensin II norepinephrine, and renal transport of electrolytes and water in normal man and in cirrhosis with ascites
46. Decreased pressor reactivity to angiotensin II in cirrhotic rats. Evidence for a post receptor defect in angiotensin action
47. Role of glucagon in splanchnic hyperemia of chronic portal hypertension
48. Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver
49. Temporal relationship between hyperaldoste hyperalcosteronism, sodium retention and ascites formation in rats with experimental cirrhosis
50. Temporal relationship between the impairment of free water excretion and antidiuretic hormone hypersecretion in rats with experimental cirrhosis
51. Temporal relationship between the decrease in arterial pressure and sodium retention in hypertensive rats with carbon tetrachloride induced cirrhosis
52. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis
53. Effects of dopamine on renal function in patients with cirrhosis
54. Reponse to dopamine hydrochloride in the hepatorenal syndrome
55. Renal function in cirrhosis and the effects of prostaglandin A1
56. The treatment of the hepatorenal syndrome with intrarenal administration of prostaglandin E1
57. The renin angiotensin system in cirrhosis. Its relation to functional renal failure
58. Acute changes in renal excretion of sodium and solute in patients with Laennec's cirrhosis, induced by the administration of the pressor amine, metaraminol
59. Renal vasodilator therapy in the hepatorenal syndrome
60. Renal and neurohumoral changes following simultaneous administration of systemic vasoconstrictors and renal vasodilators in cirrhotic patients with hepatorenal syndrome
61. Systemic, splanchnic and renal hemodynamic effects of dopaminergic dose of dopamine in patients with cirrhosis
62. Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure
63. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study
64. Total paracentesis associated with intravenous albumin in the management of patients with cirrhosis and ascites
65. Role of nitric oxide as mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis
66. Nitric oxide and portal hypertension: Its role in the regulation of intrahepatic and splanchnic vascular resistance
67. Increased blood flow through the portal system in cirrhotic rats
68. Circulation times in the splanchnic and hepatic beds in alcoholic liver disease
69. Diagnosis of functional renal failure of cirrhosis by Doppler sonography. Prognostic value of resistive index
70. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure
71. Brachial and femoral artery blood flow in cirrhosis: Relationship to kidney dysfunction
72. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion
73. Enhancement of renal function with ornipressin in a patient with decompensated cirrhosis
74. Beneficial effect of 8-ornithine vasopressin on renal dysfunction in decompensated cirrhosis
75. Gerbes AL Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis
76. TIPS in hepatorenal syndrome
77. Minetal corticoid escape in patients with compensated cirrhosis and portal hypertension
78. Hepatic hemodynamics and the renin-angiotensin aldosterone system in cirrhosis
79. Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal plasma renin, aldosterone and norepinephrine levels
80. Atrial natriureiic factor in cirrhosis with ascites: Plasma levels, cardiac release and splanchnic extraction
81. Complications of cirrhosis. Renal and circulatory dysfunction lights and shadows in an important clinical problem
82. The renin-angiotensin aldosterone system in cirrhosis
83. Renal and systemic hemodynamics in experimental cirrhosis in rats: Relation to hepatic function
84. Plasma cAMP: A hepatorenal link influencing proximal reabsorption and renal hemodynamics?
85. Renin, aldosterone and renal hemodynamics in cirrhosis with ascites
86. Effect of indomethacin and prostaglandin A1 in renal function and plasma renin activity in alcoholic liver disease
87. Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis
88. Renal effects of endogenous natriuretic peptides receptors blockade in cirrhotic rats with ascites
89. Prognostic value of spontaneous hyponatremia in cirrhosis with ascites
90. Renal nerve activity in hepatorenal syndrome
91. Hepatorenal disorders: Role of the sympathetic nervous system
92. The sympathetic nervous system in cirrhosis
93. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome
94. Endothelin-1 does not play major role in the homeostasis of arterial pressure in cirrhotic rats with ascites
95. Circulating levels of endothelin in cirrhosis
96. Increased plasma endothelin in cirrhosis. Relationship with systemic endotoxemia and response to changes in effective blood volume
97. Vasoactive agents and intrahepatic portal hypertension and fibrogenesis: Implication for therapy
98. Effect of dipyridamole on kidney function in cirrhosis
99. Arachidonic acid metabolites and the kidney in cirrhosis
100. Treatment of hepatorenal syndrome in cirrhosis
101. Refractory ascites in cirrhosis. Mechanism and management
102. Hyponatremia in cirrhosis: From pathogenesis to treatment
103. Unpredictability of clinical evaluation of renal function in cirrhosis: A prospective study
104. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis
105. Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary B2- microglobulin to discriminate functional renal failure form acute tubular damage
106. Hepatorenal syndrome without avid sodium retention
107. Spontaneous bacterial peritonitis in cirrhosis: Predictive factors of infection resolution and survival in patients treated with cefotaxime
108. Renal impairment following spontaneous bacterial peritonitis in cirrhosis. Incidence, clinical course, predictive factors and prognosis
109. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: Relationship with the development of renal impairment and mortality
110. Clinical types and drug therapy of renal impairment in cirrhosis
111. Complications of cirrhosis. Renal and circulatory dysfunction lights and shadows in an important clinical problem
112. Plasma catecholamine levels and portal venous pressure as guides to prognosis in patients with cirrhosis
113. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites
114. Reduced central blood volume in cirrhosis
115. The systemic circulation in cirrhosis
116. Influence of the degree of liver failure on systemic and splanchnic hemodynamics and on response to propranolol in patients with cirrhosis
117. Regional sympathetic nervous activity, severity of liver disease and hemodynamics in patients with cirrhosis
118. Systemic and renal hemodynamics in oliguric hepatic failure: Effect of volume expansion
119. Splanchnic hemodynamic factors in cirrhosis with refractory ascites
120. Estudio prospectivo clínico-hemodinámico del síndrome hepatorenal (SHR) en la cirrosis hepática
121. Effects of spontaneous bacterial peritonitis (SBP) on systemic and splanchnic hemodynamics in patients with cirrhosis
122. Acute effects of captopril on systemic and renal hemodynamics and renal function in cirrhotic patients with ascites
123. Effects of captopril on renal function in patients with cirrhosis and ascites
124. Hemodynamic effects of the angiotensin II receptor antagonist Irbesartan in patients with cirrhosis and portal hypertension
125. Increased sympathetic nervous activity and the effects of its inhibition with clonidine in alcoholic cirrhosis
126. Circulation times in the splanchnic and hepatic beds in alcoholic liver disease
127. Hepatic blood flow in alcoholic liver disease measured by an indicator dilution technique
128. Quantitation of portasystemic shunting from the splenic and mesenteric beds in alcoholic liver disease
129. Hyperdynamic circulation in portal-hypertensive rat model: A primary factor for maintenance of chronic portal hypertension
130. Changes in splanchnic blood flow in portal hypertensive rats
131. Role of humoral factors in the intestinal hyperemia associated with chronic portal hypertension
132. Complications of cirrhosis. I. Portal hypertension
133. Intestinal capillary filtration in acute and chronic portal hypertension
134. Intestinal microvascular adaptation in chronicc portal hypertension in the rat
135. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats
136. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats
137. Increased cerebral vascular resistance in cirrhotic patients with ascites
138. Nitric oxide: Physiology, pathophysiology, and pharmacology
139. Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats
140. Increased endothelial nitric oxide in the hyperemic vessels of portal hypertensive rats
141. Pathogenesis of arterial hypotension in cirrhotic rats with ascites: Role of endogenous nitric oxide
142. Impaired responsiveness to angiotensin II in experimental cirrhosis: Role of nitric oxide
143. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition
144. Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats
145. Mesenteric vasodilator responses in cirrhotic rats: A role for nitric oxide?
146. Nitric oxide mediates in vitro hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats
147. Role of endothelium in the abnormal response of mesenteric vessels in rats with portal hypertension and liver cirrhosis
148. Nitric oxide and endothelium as potential targets of portal hypertension
149. Hyperdynamic circulation of liver diseases forty years later: Pathophysiology and clinical consequences
150. The enteric nervous system
151. Calcitonin-gene related peptide in hepatorenal syndrome
152. Increased circulation calcitonin-gene related peptide (CGRP) in cirrhosis
153. Vasoactive intestinal peptide and calcitonin-gene related peptide and hemodynamics during human liver transplantation
154. Relation of calcitonin gene-related peptide to systemic vasodilation and central hypovolaemia in cirrhosis
155. Role of calcitonine gene-related peptide in the vascular system on the development of the hyperdynamic circulation in conscious cirrhotic rats
156. Cirrhotic cardiomiopathy: Getting to the heart of the matter
157. Effect of terlipressin administration with and without albumin in hepatorenal syndrome (HRS) (abstr). A phase-Il study
158. Endothelial dysfunction in the intrahepatic microcirculation of the cirrhotic rat
159. Hepatic vascular bed
160. Sympathetic tone modulates portal venous pressure in alcoholic cirrhosis
161. Increased sympathetic nervous activity and the effects of its inhibition with clonidine in alcoholic cirrhosis
162. Paracentesis-induced circulatory dysfunction: Mechanism and effect on hepatic hemodynamics in cirrhosis
163. Peritoneovenous shunt in the management of the hepatorenal syndrome
164. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites
165. Treatment of patients with cirrhosis and refractory ascites by LeVeen shunt with titanium tip. Comparison with therapeutic paracentesis
166. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome-experience in 300 patients
167. Sequential treatment of hepatorenal syndrome and posthepatic cirrhosis by intrahepatic portosystemic shunt (TIPS) and liver transplantation
168. Impact of pretransplant renal function on survival after liver transplantation
169. The hepatorenal syndrome in liver transplant recipients
170. Effects of renal impairment on liver transplantation
171. Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis
172. Terlipressin plus albumin infusion is an effective and safe therapy of hepatorenal syndrome
173. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine
174. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: A pilot study
175. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide
176. Noradrenalin for treatment of type 1 hepatorenal syndrome (HRS)
177. Functional renal failure in cirrhosis. Recovery after portacaval shunt
178. The hepatorenal syndrome: Recovery after portacaval shunt
179. Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant patients with hepatorenal syndrome: A phase II study
180. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems
181. Treatment of hepatorenal syndrome with the transjugular intrahepatic shunt (TIPS)
182. TIPS for hepatorenal syndrome
183. Dialysis hemofiltration, and other extracorporeal techniques in the treatment of renal complications of liver disease
184. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized controlled clinical trial
185. Role of molecular adsorbent recycling system (MARS) in the treatment of acute exacerbation of chronic liver failure
186. Effect of plasma volume expansion on renal impaiment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis
187. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial